News
09-22-2009, 03:12 AM
Pfizer Oncology will present data from across its portfolio, including results from long-term follow-up of Aromasin® (exemestane tablets) in a study of early breast cancer,1 updated study results from a Phase 3 study of Sutent® (sunitinib malate) in pancreatic neuroendocrine tumors (NET),2 and early-stage research of investigational agents PF-023410663 and figitumumab (CP-751,871)4 in patients with non-small cell lung cancer (NSCLC).
More... (http://www.medicalnewstoday.com/articles/164642.php)
More... (http://www.medicalnewstoday.com/articles/164642.php)